Mar 04, 2026 4:00pm EST MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock
Mar 02, 2026 10:45pm EST MAIA Biotechnology Announces Pricing of $30 Million Underwritten Public Offering of Common Stock
Mar 02, 2026 5:00pm EST MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
Feb 24, 2026 8:45am EST MAIA Biotechnology’s Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market
Jan 20, 2026 10:15am EST MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum
Dec 24, 2025 8:01am EST MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings
Dec 11, 2025 1:00pm EST MAIA’s Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates
Dec 11, 2025 9:00am EST MAIA Biotechnology Announces First Patient Dosed in THIO-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer
Dec 11, 2025 8:00am EST MAIA Leadership Continues Insider Buying in 2025 and Trial Data Signals Breakout Potential
